Compare FERG & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FERG | ZTS |
|---|---|---|
| Founded | 1887 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.7B | 48.7B |
| IPO Year | 2024 | 2012 |
| Metric | FERG | ZTS |
|---|---|---|
| Price | $262.06 | $122.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $268.54 | $155.18 |
| AVG Volume (30 Days) | 1.2M | ★ 2.8M |
| Earning Date | 06-02-2026 | 05-07-2026 |
| Dividend Yield | 1.39% | ★ 1.78% |
| EPS Growth | 9.26 | ★ 10.05 |
| EPS | 2.90 | ★ 6.02 |
| Revenue | ★ $30,762,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | $7.98 | $5.68 |
| Revenue Next Year | $5.86 | $4.86 |
| P/E Ratio | $88.97 | ★ $19.80 |
| Revenue Growth | ★ 3.80 | 2.28 |
| 52 Week Low | $158.68 | $113.30 |
| 52 Week High | $271.64 | $172.23 |
| Indicator | FERG | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 56.63 |
| Support Level | $217.40 | $120.22 |
| Resistance Level | $268.85 | $129.28 |
| Average True Range (ATR) | 5.75 | 2.69 |
| MACD | 3.18 | 0.72 |
| Stochastic Oscillator | 91.97 | 93.02 |
Ferguson distributes plumbing and HVAC products to North American repair, maintenance and improvement, new construction, and civil infrastructure markets. It serves over 1 million customers and sources products from 36,000 suppliers. Ferguson engages customers through approximately 1,800 North American branches, over the phone, online, and in residential showrooms. According to Modern Distribution Management, Ferguson is the largest plumbing distributor and second-largest HVAC distributor (next to Watsco) in North America. The firm sold its UK business in 2021 and is now solely focused on the North American market.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.